First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the <sup>111</sup>In-ABY-025 Affibody Molecule
Jens Sørensen(Uppsala University), Henrik Lindman(Uppsala University), Anders Wennborg(Affibody (Sweden)), Mark Lubberink(Uppsala University), Gunnar Åström(Uppsala University), Dan Sandberg(Uppsala University), Ulrike Garske‐Román(Uppsala University Hospital), Vladimir Tolmachev(Uppsala University), Mattias Sandström(Uppsala University Hospital), Jörgen Carlsson(Uppsala University Hospital), Joachim Feldwisch(Uppsala University)
Cited by 260
Related Papers
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
|PLoS ONE|2009|504
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
|The Lancet|2000|343
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [<sup>68</sup>Ga]ABY-025 Affibody PET/CT
|Theranostics|2015|269
In Vivo Visualization of Amyloid Deposits in the Heart with <sup>11</sup>C-PIB and PET
|Journal of Nuclear Medicine|2012|258